Background Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers. Methods In this multicenter, prospective, open-label, single-group study, we evaluated 67 patients who had acute major bleeding within 18 hours after the administration of a factor Xa inhibitor. The patients all received a bolus of andexanet followed by a 2-hour infusion of the drug. Patients were evaluated for changes in measures of anti-factor Xa activity and were assessed for clinical hemostatic efficacy during a 12-hour period. All the patients were subsequently followed for 30 days. The efficacy population of 47 patients had a baseline value for anti-factor Xa ac...
Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to ...
BACKGROUND AND PURPOSE: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to ...
Background The lack of an antidote against factor Xa inhibitors in case of major bleeding or need fo...
BackgroundAndexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that ha...
BACKGROUND: Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that ...
Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of ...
BACKGROUND Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for r...
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for ...
International audienceBackground: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) ...
Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, alb...
Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, alb...
Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor...
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is acco...
<div><p>Introduction</p><p>Increasing use of factor Xa (FXa) inhibitors necessitates effective rever...
Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleedi...
Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to ...
BACKGROUND AND PURPOSE: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to ...
Background The lack of an antidote against factor Xa inhibitors in case of major bleeding or need fo...
BackgroundAndexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that ha...
BACKGROUND: Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that ...
Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of ...
BACKGROUND Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for r...
BACKGROUND: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for ...
International audienceBackground: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) ...
Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, alb...
Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, alb...
Andexanet alfa is a recombinant modified factor Xa protein that has been developed to reverse factor...
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is acco...
<div><p>Introduction</p><p>Increasing use of factor Xa (FXa) inhibitors necessitates effective rever...
Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleedi...
Background and Purpose: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to ...
BACKGROUND AND PURPOSE: Andexanet alfa is a recombinant modified human FXa (factor Xa) developed to ...
Background The lack of an antidote against factor Xa inhibitors in case of major bleeding or need fo...